Intrinsiqq

Vicore Pharma Holding AB (VICO.XSTO) Financials

All currency values in kr millions unless otherwise noted

Scroll

Income Statement
TTM
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenuekr 4kr 4kr 109kr 0kr 0kr 0
Gross Profitkr 4kr 4kr 109kr 0kr 0kr 0
Total Operating Expenseskr 530kr 458kr 300kr 321kr 287kr 293
Operating Income-kr 526-kr 454-kr 190-kr 321-kr 287-kr 293
Non-Operating
Net Interest Expense-kr 40-kr 0-kr 0-kr 0-kr 0-kr 0
Income Tax Expensekr 0kr 0-kr 0-kr 0-kr 0-kr 0
Net Income
Net Income-kr 502-kr 477-kr 169-kr 311-kr 288-kr 296
Per Share Data
Revenue Per Sharekr 0.01kr 0.02kr 0.80kr 0.00kr 0.00kr 0.00
EPS (Basic)-kr 1.92-kr 1.99-kr 1.23-kr 3.13-kr 3.88-kr 4.14
EPS (Diluted)-kr 1.92-kr 1.99-kr 1.23-kr 3.13-kr 3.88-kr 4.14
Shares Outstanding281.5M239.9M136.8M99.2M74.2M71.6M

Vicore Pharma Holding AB (VICO.XSTO) financials: revenue, profit and margins

Vicore Pharma Holding AB (VICO.XSTO) generated about SEK 4 million in revenue and -SEK 502 million in net income (a -12,569.8% net margin) over the trailing twelve months, growing at roughly -96.5% a year. Figures are from company filings; this is analysis, not investment advice.

Frequently asked

What is Vicore Pharma Holding AB's (VICO.XSTO) revenue?+

Vicore Pharma Holding AB generated about SEK 4 million in revenue over the trailing twelve months. Revenue has grown at roughly -96.5% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Vicore Pharma Holding AB profitable?+

Vicore Pharma Holding AB reported about -SEK 502 million in net loss over the trailing twelve months, a net margin of roughly -12,569.8%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are Vicore Pharma Holding AB's profit margins?+

Vicore Pharma Holding AB runs a gross margin of about 100.0%, an operating margin of about -13,161.7%, a net margin of about -12,569.8%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How fast is Vicore Pharma Holding AB growing?+

Vicore Pharma Holding AB's revenue has compounded at roughly -96.5% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside VICO.XSTO's margins and free cash flow. This is analysis from company filings, not investment advice.

How the market compares: How many US companies are profitable

Related stocks: Biotechnology

Spot a number that looks wrong?

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.